Top Markets
Coin of the day
Anhui Anke Biotechnology (Group) Co., Ltd. Anhui Anke Biotechnology (Group) Co., Ltd.

Anhui Anke Biotechnology (Group) Co., Ltd.

300009
Rankning i aktier #6265
Anhui Anke Biotechnology (Group) Co., Ltd. is engaged in the research,... Anhui Anke Biotechnology (Group) Co., Ltd. is engaged in the research, manufacturing, and global distribution of pharmaceutical goods, serving both domestic Chinese and international markets. Its flagship offerings include Ansomone, a brand of recombinant human growth hormone administered via injection, and the Anterferon line, which comprises recombinant human interferon alpha 2b in various forms such as lyophilized powder, liquid, and prefilled syringes for injection, alongside creams, eye drops, and suppositories. The company also supplies an array of diagnostic kits, including those for detecting anti-sperm antibodies, performing semen leukocyte peroxidase staining, single-use semen processing, sperm hypo-osmotic staining, assessing sperm viability, analyzing sperm morphology, determining sperm acrosin levels, identifying sperm DNA fragmentation, and for leptin and immunohistochemical analyses. Furthermore, their product portfolio extends to adhesive bandages, liquid oral medications, various topical formulations (including creams and ointments), active pharmaceutical ingredients (APIs) derived from peptides, cosmetic and anti-aging treatments, and synthetic pharmaceutical compounds available as powders, dripping pills, and both tablets and capsules. Moreover, Anke Biotechnology offers genetic testing solutions, encompassing kits for autosomal, sex chromosome, and combined autosomal and sex chromosome analyses, along with complete paternity testing packages. They also develop biological immunotherapy treatments for tumors and provide specialized DNA testing services. Established in 2000, the firm's headquarters are situated in Hefei, China.
Aktiekurs
$1.28
Marknadsvärde
$2.13B
Förändring (1 dag)
0.34%
Förändring (1 år)
-18.11%
Land
CN
Handel Anhui Anke Biotechnology (Group) Co., Ltd. (300009)

Kategori

Vinst för Anhui Anke Biotechnology (Group) Co., Ltd. (300009)
Vinst i 2026 TTM: 0
Enligt de senaste finansiella rapporterna från Anhui Anke Biotechnology (Group) Co., Ltd. är företagets nuvarande vinst 0. År 2026 hade företaget en vinst på 0, lika med vinsten år 2026 som var 0. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Anhui Anke Biotechnology (Group) Co., Ltd. från 2026 till 2026
Vinst vid slutet av varje år
År Vinst Ändra
Inte tillräckligt med data för de angivna datumen.
Vinst för liknande företag eller konkurrenter
Företag Vinst Skillnad i vinst Land
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH